About Stereotaxis

Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. Stereotaxis’ core Epoch™ Solution includes the Niobe® ES remote magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems, and the Vdrive™ robotic navigation system and consumables, which have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere.

Press Releases

Stay updated on Stereotaxis news. Click to access press releases, stock updates, and other investor information.

#TogetherTo100K

Surpassing 100,000 patients treated is an impressive milestone. It is a testament to the significant clinical value that our technology provides patients and physicians in the electrophysiology field. It also is a reminder of the robust validation of our technology. Stereotaxis stands head-and-shoulders above all others as the global leader in endovascular robotics.

I want to thank and congratulate all the employees, physicians, hospital administrators, corporate partners and investors who made reaching this milestone possible. There is a saying that whoever saves a life is considered to have saved an entire world. We take great pride in each patient we treat and life we improve. We look forward to continuing to advance our technology and support robotic ablation practices such that hundreds of thousands of additional patients suffering from arrhythmias can benefit from the precision and safety that robotics provides.

David Fischel
Chairman & CEO

Advocates